title: Mixed low- and high-grade papillary urothelial carcinoma: histopathogenetic and clinical significance.
abstract: There are two pathways of urothelial carcinogenesis: low-grade urothelial carcinoma (LGUC) with low rates of gene alterations and high-grade urothelial carcinoma (HGUC) with numerous gene alterations. HGUC often displays strong reactivity for cytokeratin 20 (CK20) and p16. Despite distinct molecular changes, urothelial carcinoma (UC) with both low- and high-grade features is not uncommon. We examined cases with patterns of mixed low- and high-grade UC (MLHGUC). Consecutive cases of UC at our institution were reviewed. There were 45 cases that showed a mixture of both LGUC and HGUC. IHC for CK5, CK20, CD44, p16, and Ki67 was performed. Areas of HGUC displayed strong and diffuse reactivity for p16, CK20, and Ki67 in 20-50 % of the tumor, while LGUC areas had negative or focal reactivity for CK20 and Ki67 in 10-30 %. There were two distinct cohorts of MLHGUC: patients with a history of LGUC (group A) and those without (group B). Group A patients (n = 8) had a history of LGUC for 1-10 years. The tumor specimens weighed 1.5 ± 1.7 g and had HGUC components of 25 ± 20 % of the tissue. Superficial invasion was present in one case. All tumors had BCG treatment with one recurrence. In group B (n = 37), tumor specimens weighed 3 ± 3.9 g and had HGUC components in 43 ± 21 % of the tissue. Superficial invasion was present in five cases, and muscle invasion with lung metastasis occurred in one case. Four cases were refractory to BCG with an increased proportion of HGUC, and one case requiring cystectomy. Differences in size and proportion of HGUC between groups A and B MLHGUC were significant (P < 0.05), with group B presenting with a higher tumor burden and proportion of HGUC. MLHGUC is diagnostically challenging and is commonly assigned high grade since this determines prognosis. Group A MLHGUC likely develops as a result of progression from LGUC, whereas group B MLHGUC likely develops de novo, is associated with larger tumors, shows a higher proportion of HGUC, and follows a worse prognosis. Despite the similar histology of groups A and B, assignment to HGUC in a binary system may mask important prognostic information.
authors.affiliation: Department of Pathology and Laboratory Medicine, The Ottawa Hospital, University of Ottawa, Ottawa, Ontario, Canada, ktmai@ottawahospital.on.ca.
authors.forename: Kien T
authors.initials: KT
authors.lastname: Mai
authors.forename: Trevor A
authors.initials: TA
authors.lastname: Flood
authors.forename: Phillip
authors.initials: P
authors.lastname: Williams
authors.forename: Zuzana
authors.initials: Z
authors.lastname: Kos
authors.forename: Eric C
authors.initials: EC
authors.lastname: Belanger
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis; D002291:Carcinoma, Papillary / Q000145:classification / Q000473:pathology*; D002295:Carcinoma, Transitional Cell / Q000145:classification / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D012189:Retrospective Studies; D001749:Urinary Bladder Neoplasms / Q000145:classification / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor
references.citation: Expert Rev Anticancer Ther. 2010 Jun;10(6):865-80
references.pmid: 20553211
references.citation: Lancet. 1993 Aug 21;342(8869):469-71
references.pmid: 8102431
references.citation: Br J Urol. 1996 Dec;78(6):870-5
references.pmid: 9014711
references.citation: Urology. 2006 Mar;67(3 Suppl 1):11-7; discussion 17-8
references.pmid: 16530068
references.citation: Am J Pathol. 2001 Jun;158(6):1955-9
references.pmid: 11395371
references.citation: J Urol. 1998 Dec;160(6 Pt 1):1971-4
references.pmid: 9817302
references.citation: Arch Pathol Lab Med. 2010 Aug;134(8):1160-3
references.pmid: 20670136
references.citation: Urol Int. 2004;73(3):201-8
references.pmid: 15539837
references.citation: Urology. 2004 Jul;64(1):157-61
references.pmid: 15245962
references.citation: Pathol Res Pract. 2008;204(10):707-17
references.pmid: 18572327
references.citation: Urol Oncol. 2010 Jul-Aug;28(4):401-8
references.pmid: 20610278
references.citation: Am J Clin Pathol. 2004 May;121(5):679-87
references.pmid: 15151208
references.citation: Appl Immunohistochem Mol Morphol. 2012 May;20(3):264-71
references.pmid: 22498670
references.citation: In Vivo. 2008 Jul-Aug;22(4):493-501
references.pmid: 18712178
references.citation: Virchows Arch. 2002 Aug;441(2):109-16
references.pmid: 12189499
references.citation: Am J Clin Pathol. 2010 May;133(5):788-95
references.pmid: 20395527
references.citation: Virchows Arch. 2003 Dec;443(6):734-40
references.pmid: 14534785
references.citation: J Clin Oncol. 2006 Aug 1;24(22):3664-71
references.pmid: 16877735
references.citation: Int J Clin Exp Pathol. 2012;5(9):882-91
references.pmid: 23119105
references.citation: Am J Clin Pathol. 1994 Feb;101(2):166-76
references.pmid: 7906919
references.citation: Cancer Res. 1997 Apr 1;57(7):1217-21
references.pmid: 9102201
references.citation: Eur Urol. 2000 May;37(5):601-4
references.pmid: 10765100
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: Mod Pathol. 2001 Apr;14(4):267-72
references.pmid: 11301341
references.citation: Int Urol Nephrol. 2003;35(2):169-73
references.pmid: 15072488
references.citation: Scand J Urol Nephrol Suppl. 2008 Sep;(218):154-65
references.pmid: 18815930
references.citation: Mod Pathol. 2000 Dec;13(12):1315-23
references.pmid: 11144928
references.citation: Urol J. 2004 Summer;1(3):177-9
references.pmid: 17914684
references.citation: Histol Histopathol. 2003 Jul;18(3):969-80
references.pmid: 12792907
references.citation: Pathol Int. 2010 Jan;60(1):1-8
references.pmid: 20055945
references.citation: Semin Diagn Pathol. 1997 May;14(2):98-108
references.pmid: 9179971
references.citation: Oncogene. 1999 Apr 22;18(16):2657-61
references.pmid: 10353610
references.citation: Crit Rev Oncol Hematol. 2003 Aug;47(2):83-9
references.pmid: 12900003